An update to the American Radium Society's appropriate use criteria of lower grade gliomas: Integration of IDH inhibitors.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 39557126.
- Also identified by DOI 10.1016/j.radonc.2024.110640.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The ARS brain committee recommends that vorasidenib may be appropriate for recurrent or residual IDH-mutant grade 2 oligodendroglioma or astrocytoma. Vorasidenib is usually not appropriate for completely resected grade 2 oligodendroglioma or astrocytoma, any grade 3 oligodendroglioma or astrocytoma, or combined with radiotherapy and/or chemotherapy for any grade 2-3 glioma.
Medical subject headings
- Isocitrate Dehydrogenase
- Brain Neoplasms
- Glioma